entered an agreement with Celsis In Vitro Technologies
, such that Promega will co-market its bioluminescent ADME/Tox
assays with Celsis’ line of high quality cryopreserved plateable hepatocytes.
Celsis will pre-qualify lots of cryoplateable hepatocytes for use with specific P450-Glo CYP Assays to study cytochrome P450 gene induction and inhibition. Celsis will also validate cryopreserved lots of hepatocytes for use with Promega GSH-Glo Glutathione Assay for investigating mechanisms of hepatotoxicity.
Determining whether a particular lot of hepatocytes will work for a given application is time-consuming and costly. Even when a suitable lot of hepatocytes is identified, current LC/MS technologies for measuring gene expression, enzyme activity, or metabolite formation are expensive or involve lengthy incubation times that often require several days to process.
Promega and Celsis believe that their partnership will enable scientists to quickly and easily identify both products that have been validated to work together in less time, with fewer resources, and with increased efficiency.
“Combining validated biologic components with Promega’s ultrasensitive and dynamic luminescence assay detection technology is a significant benefit to scientists,” according to Philip M. Vorwald, vp and GM of Celsis IVT. “Our research has confirmed the higher predictive value and accuracy of the combined assay for identifying adverse side effects in new chemical entities.”
To comment on this story, go to BLOGbiotech.